European Society for Medical Oncology

Type: Organization
Name: European Society for Medical Oncology
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

IFEMA has further cemented its status as a key venue for the international congress sector

IFEMA's burgeoning popularity as a venue for international conventions and congresses is a key factor behind Madrid's rise to second place in the ICCA's global city ranking, with an ever increasing number of major international events choosing to take ... [Published IFEMA - Aula - Jul 09 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 1 reports

Equal Benefit from Cetuximab and Bevacizumab in mCRC

“The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study was designed to determine if one was better than the other in first-line for patients with colon ... [Published American Journal of Managed Care - Jun 30 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

New Product Improves Survival in Refractory Metastatic CRC

The investigational product TAS-102 (Taisho) has shown an improvement in overall survival in patients with metastatic colorectal cancer refractory to other therapies. The results, from a phase 3 study known as RECOURSE, will be used for submission to ... [Published Diabetes Care - Jun 30 2014]
First reported Jun 28 2014 - Updated Jun 29 2014 - 1 reports

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wildtype MCRC

| AAAS(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Ga ... [Published BioPortfolio - Jun 28 2014]
First reported Jun 28 2014 - Updated Jun 29 2014 - 1 reports

Improved survival with TAS102 in mets colorectal cancer refractory to standard therapies

| AAAS(European Society for Medical Oncology) The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th ... [Published BioPortfolio - Jun 28 2014]
First reported Jun 28 2014 - Updated Jun 28 2014 - 1 reports

ESMO: Better Survival in GI Cancers

(MedPage Today) -- Two different antibodies had a similar impact on survival when added to chemotherapy for patients with newly diagnosed colorectal cancer, investigators reported. The study was among several notable reports from the European Society ... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 28 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Immunotherapy Holds Promise in Pancreatic Cancer

A new version of a standard chemotherapy has shown an improvement in survival in metastatic pancreatic cancer in patients who had previously been treated with gemcitabine.The investigational product, a novel encapsulation of irinotecan in a long-circulating ... [Published Diabetes Care - Jun 26 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Adjuvant Chemo, Radiation Recommended for R1-resected Cancer Patients

the Chemotherapy Advisor take:In a survey completed by the European Society for Medical Oncology Young Oncologists Committee, 700 specialists provided real-world responses about the treatment of patients with lung cancer who have had their tumors incompletely ... [Published Chemotherapy Advisor - Jun 19 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

ESMO welcomes the adoption of the Clinical Trials Regulation by the E.U.

The European Society for Medical Oncology (ESMO) has welcomed the adoption of the Clinical Trials Regulation by the E.U.The new framework acknowledges the importance of using data stored for a clinical trial beyond the end of the study itself, for research ... [Published Center Watch - Jun 18 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 2 reports

Merrimack Pharmaceuticals Inc. Announces Oral Presentation Of Additional Data Results In Phase 3 NAPOLI-1 Study At The

6/17/2014 8:50:14 AMCAMBRIDGE, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that results of the successful Phase 3 NAPOLI-1 study in metastatic pancreatic cancer will be communicated in an oral ... [Published BioSpace - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 4 reports

Medical research safeguarded in Europe

PUBLIC RELEASE DATE: 16-Jun-2014Lugano, Switzerland, 16 June 2014 -- The European Society for Medical Oncology (ESMO), the leading pan-European association representing medical oncology professionals, has welcomed the adoption of the Clinical Trials Regulation ... [Published EurekAlert! - Jun 16 2014]
First reported Jun 10 2014 - Updated Jun 10 2014 - 3 reports

ESMO survey sheds light on common clinical practice for incompletely resected lung cancer

-- A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology ... [Published Bio-Medicine - Jun 10 2014]

Quotes

...on the data, ESMO spokesperson Dirk Arnold , Director of the Department of Medical Oncology , Tumour Biology Centre in Freiburg, Germany , said: "This was a long awaited phase III trial with a head-to-head comparison of two different molecular approaches: epidermal growth factor receptor (EGFR) blocking by cetuximab on one side and antiangiogenic (anti-vascular endothelial growth factor [VEGF]) inhibiting treatment with bevacizumab on the other side, both in combination with any standard first-line chemotherapy in metastatic colorectal cancer. The trial is important because the primary endpoint was overall survival. The FIRE-3 trial presented last year indicated that there may be an overall survival benefit with cetuximab but overall survival was only a secondary endpoint and data was inconclusive."
"The results of the RECOURSE study demonstrate a clinically relevant improvement in the overall survival of patients with metastatic colorectal cancer whose disease had progressed after treatment with standard therapies" principal investigator Robert J Mayer, MD, from the Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School in Boston, commented...
"The RECOURSE results suggest the efficacy of TAS-102 as a new treatment option for patients with mCRC" said Dr. Atsushi Ohtsu, one of the principal researchers of this study and the Director of the Exploratory Oncology Research & Clinical Trial Center...
...and their families, who participated in this trial," said Fabio Benedetti, M D , Taiho Oncology's Senior Vice President and Chief Medical Officer. "The TAS-102 RECOURSE study data presented will serve as the foundation for our regulatory submissions, which we plan in the U S at the end of 2014 and in Europe in the first quarter of 2015."

More Content

All (48) | News (44) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
A Pre-Earnings Update On Gilead [Published Seeking Alpha - Jul 10 2014]
Cetuximab or bevacizumab with combi chemo equiv... [Published HispanicBusiness.com - Jul 10 2014]
IFEMA has further cemented its status as a key ... [Published IFEMA - Aula - Jul 09 2014]
Study Shows TAS-102 Improves Survival in Refrac... [Published P&T Community - Jun 30 2014]
New Product Improves Survival in Refractory Met... [Published Diabetes Care - Jun 30 2014]
Equal Benefit from Cetuximab and Bevacizumab in... [Published American Journal of Managed Care - Jun 30 2014]
Taiho Pharmaceutical Announces Results From TAS... [Published Bernama - Jun 30 2014]
Value tops the agenda at ASCO cancer conference [Published Pharmafocus - Jun 30 2014]
Taiho Pharmaceutical Announces Results from TAS... [Published Asia Net - Jun 30 2014]
ESMO: Better Survival in GI Cancers [Published MedPageToday.com - medical news plus CME for ph ... - Jun 28 2014]
Taiho Oncology presents TAS-102 Phase III RECOU... [Published News-Medical.Net - Jun 28 2014]
Improved survival with TAS102 in mets colorecta... [Published BioPortfolio - Jun 28 2014]
Taiho Oncology, Inc. Announces Results from TAS... [Published Asia Net - Jun 28 2014]
Cetuximab or bevacizumab with combi chemo equiv... [Published BioPortfolio - Jun 28 2014]
Immunotherapy Holds Promise in Pancreatic Cancer [Published Diabetes Care - Jun 26 2014]
Merrimack Pharmaceuticals Presents Data From Ph... [Published Stock Nod - Jun 25 2014]
Life for Vital Options following Death of Found... [Published Oncology Times - Jun 25 2014]
Radiation Therapy: Curative Option for RCC? [Published General Medicine eJournal - Jun 23 2014]
2 Top Catalysts This Week: AstraZeneca and Merr... [Published Motley Fool Discussion Boards - Jun 22 2014]
Adjuvant Chemo, Radiation Recommended for R1-re... [Published Chemotherapy Advisor - Jun 19 2014]
ESMO welcomes the adoption of the Clinical Tria... [Published Center Watch - Jun 18 2014]
Cardiotoxicity of Targeted Agents in Oncology: ... [Published Cancernetwork.com - Jun 18 2014]
Merrimack Pharmaceuticals Inc. Announces Oral P... [Published BioSpace - Jun 17 2014]
Promising results from new therapy for pancreat... [Published Chemotherapy Advisor - Jun 17 2014]
Merrimack To Announce Phase 3 Napoli-1 Study Re... [Published RTTNews.com - Jun 17 2014]
Merrimack Pharma Will Present Added Data Result... [Published Benzinga.com - Jun 17 2014]
Updated Summary: Endometrial cancer. [CancerCon... [Published National Guideline Clearinghouse - Jun 16 2014]
Medical research safeguarded in Europe [Published EurekAlert! - Jun 16 2014]
Medical research safeguarded in Europe [Published Bio-Medicine - Jun 16 2014]
Medical Research Safeguarded in Europe [Published Michigan Live - Jun 16 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ESMO: Better Survival in GI Cancers [Published MedPageToday.com - medical news plus CME for ph ... - Jun 28 2014]
(MedPage Today) -- Two different antibodies had a similar impact on survival when added to chemotherapy for patients with newly diagnosed colorectal cancer, investigators reported. The study was among several notable reports from the European Society ...
Medical Research Safeguarded in Europe [Published PR Newswire: Health - Jun 16 2014]
LUGANO, Switzerland, June 16, 2014 /PRNewswire/ --ESMO welcomes the adoption of the Clinical Trials Regulation by the EUThe European Society for Medical Oncology (ESMO) has welcomed the adoption of the Clinical Trials Regulation by the EU, entering into ...
Biothera to Present Phase 2b NSCLC Data at ESMO... [Published Business Wire Health News - Mar 27 2014]
EAGAN, Minn.--(BUSINESS WIRE)--Biothera will present data from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology’s 2014 European Lung Cancer Conference on March 28 in Geneva, Switzerland. The ...
1

Press Releases

sort by: Date | Relevance
L'absence de traitement des douleurs cancéreuse... [Published PR Newswire - Nov 28 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.